Novonordisk the leading Danish company for producing anti diabetic drugs announces positive results for phase II testing of the oral hypoglycemic semaglutide.
In the trails semaglutide appeared to be safe and well tolerated with nausea and vomiting diminished over time.
“We are very pleased with the results of this trial confirming the potential of semaglutide to treat type 2 diabetes, both as a once weekly subcutaneous injection and as a once daily tablet”
Said Mads Krogsgaard Thomsen
executive vice president and chief science
officer of Novo Nordisk
Full announcement HERE.